PSMA target radiotherapy for diagnosis and treatment of prostate cancer

摘要

The present invention relates to a pharmaceutical composition for diagnosing and treating prostate cancer with the ability to target PSMA, and the compounds provided by one aspect of the present invention are structurally conjugated to a radioactive metal conjugated chelator and The PDA protein has a glutamate urea lysine conjugated with an aryl group that can be further bound.The conjugation between the glutamic acid urea lysine compound and the chelator comprises a polar spacer to play a role in reducing non-specific conjugation in vivo and is rapidly removed from critical organs but not from prostate cancer.These properties reduce radiation exposure to normal tissues and organs caused by therapeutic radioisotope conjugated compounds, thereby reducing side effects.In addition, compounds containing phenyl groups having a conjugate to albumin have increased residence time in the blood, thereby accumulating in prostate cancer.